Advances in diagnostic testing for Alzheimer disease.

Suzanne E. Schindler, Jonathan McConathy, Beau M. Ances, Marc I. Diamond

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The diagnosis of Alzheimer disease (AD) dementia is based primarily on the clinical history and examination, but advances in understanding the pathophysiology of AD have led to new diagnostic methods. When used appropriately, the tests can provide strong positive or negative evidence AD dementia. This article described which patients may benefit from additional testing using Cerebrospinal Fluid (CSF) biomarkers, amyloid imaging, quantitative structural magnetic resonance imaging (MRI), and fluoro-deoxyglucose positron emission tomography (FDG-PET).

Original languageEnglish (US)
Pages (from-to)401-405
Number of pages5
JournalMissouri Medicine
Volume110
Issue number5
StatePublished - Sep 2013

Fingerprint

Alzheimer Disease
Deoxyglucose
Amyloid
Positron-Emission Tomography
Cerebrospinal Fluid
Biomarkers
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schindler, S. E., McConathy, J., Ances, B. M., & Diamond, M. I. (2013). Advances in diagnostic testing for Alzheimer disease. Missouri Medicine, 110(5), 401-405.

Advances in diagnostic testing for Alzheimer disease. / Schindler, Suzanne E.; McConathy, Jonathan; Ances, Beau M.; Diamond, Marc I.

In: Missouri Medicine, Vol. 110, No. 5, 09.2013, p. 401-405.

Research output: Contribution to journalArticle

Schindler, SE, McConathy, J, Ances, BM & Diamond, MI 2013, 'Advances in diagnostic testing for Alzheimer disease.', Missouri Medicine, vol. 110, no. 5, pp. 401-405.
Schindler SE, McConathy J, Ances BM, Diamond MI. Advances in diagnostic testing for Alzheimer disease. Missouri Medicine. 2013 Sep;110(5):401-405.
Schindler, Suzanne E. ; McConathy, Jonathan ; Ances, Beau M. ; Diamond, Marc I. / Advances in diagnostic testing for Alzheimer disease. In: Missouri Medicine. 2013 ; Vol. 110, No. 5. pp. 401-405.
@article{00eef129efdf40029074c657e49460e2,
title = "Advances in diagnostic testing for Alzheimer disease.",
abstract = "The diagnosis of Alzheimer disease (AD) dementia is based primarily on the clinical history and examination, but advances in understanding the pathophysiology of AD have led to new diagnostic methods. When used appropriately, the tests can provide strong positive or negative evidence AD dementia. This article described which patients may benefit from additional testing using Cerebrospinal Fluid (CSF) biomarkers, amyloid imaging, quantitative structural magnetic resonance imaging (MRI), and fluoro-deoxyglucose positron emission tomography (FDG-PET).",
author = "Schindler, {Suzanne E.} and Jonathan McConathy and Ances, {Beau M.} and Diamond, {Marc I.}",
year = "2013",
month = "9",
language = "English (US)",
volume = "110",
pages = "401--405",
journal = "Missouri Medicine",
issn = "0026-6620",
publisher = "Missouri State Medical Association",
number = "5",

}

TY - JOUR

T1 - Advances in diagnostic testing for Alzheimer disease.

AU - Schindler, Suzanne E.

AU - McConathy, Jonathan

AU - Ances, Beau M.

AU - Diamond, Marc I.

PY - 2013/9

Y1 - 2013/9

N2 - The diagnosis of Alzheimer disease (AD) dementia is based primarily on the clinical history and examination, but advances in understanding the pathophysiology of AD have led to new diagnostic methods. When used appropriately, the tests can provide strong positive or negative evidence AD dementia. This article described which patients may benefit from additional testing using Cerebrospinal Fluid (CSF) biomarkers, amyloid imaging, quantitative structural magnetic resonance imaging (MRI), and fluoro-deoxyglucose positron emission tomography (FDG-PET).

AB - The diagnosis of Alzheimer disease (AD) dementia is based primarily on the clinical history and examination, but advances in understanding the pathophysiology of AD have led to new diagnostic methods. When used appropriately, the tests can provide strong positive or negative evidence AD dementia. This article described which patients may benefit from additional testing using Cerebrospinal Fluid (CSF) biomarkers, amyloid imaging, quantitative structural magnetic resonance imaging (MRI), and fluoro-deoxyglucose positron emission tomography (FDG-PET).

UR - http://www.scopus.com/inward/record.url?scp=84891650982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891650982&partnerID=8YFLogxK

M3 - Article

C2 - 24279191

AN - SCOPUS:84891650982

VL - 110

SP - 401

EP - 405

JO - Missouri Medicine

JF - Missouri Medicine

SN - 0026-6620

IS - 5

ER -